Patients received two subcutaneous injections of omalizumab at one of three dosage levels ( 450 , 525 , or 600mg ) , chosen according to baseline IgE ( 300-2000IU / mL ) and bodyweight ( 40-150kg ) , with a 14-day interval between injections .